Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Green

Showing results (871-880 of 964) with videos related to

Pageof 97
Sort By:
The Journal of Clinical Investigation|September 1, 1996
Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltiprazP J O'Dwyer, C E Szarka, K S Yao, et al.
Schizophrenia Research|July 23, 2016
Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processingAmanda McCleery, Junghee Lee, Alan P Fiske, et al.
Schizophrenia Research|February 26, 2019
The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trialDestiny L Peterson, Christopher A Webb, Jared W Keeley, et al.
Schizophrenia Bulletin|February 25, 2011
Social cognition in schizophrenia, Part 1: performance across phase of illnessMichael F Green, Carrie E Bearden, Tyrone D Cannon, et al.
Journal of Gastrointestinal Oncology|November 16, 2023
Identification of an optimal mutant allele frequency to detect activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomasBennett A Caughey, Kumiko Umemoto, Michelle F Green, et al.
Molecular Diagnosis & Therapy|June 7, 2025
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue UsageMichelle F Green, Zachary D Wallen, Heidi C Ko, et al.
Biological Psychiatry|May 3, 2011
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disordersCameron S Carter, Deanna M Barch, Edward Bullmore, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 12, 2021
The clinical characterization of the patient with primary psychosis aimed at personalization of managementMario Maj, Jim van Os, Marc De Hert, et al.
Journal of Abnormal Psychology|October 15, 2014
Social cognition and functional outcome in schizophrenia: The moderating role of cardiac vagal toneHolly K Hamilton, Jane C Sun, Michael F Green, et al.
Biological Psychiatry|September 1, 2004
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteriaMichael F Green, Keith H Nuechterlein, James M Gold, et al.
Pageof 97

Showing results (871-880 of 964) with videos related to

Sort By:
Pageof 97
The Journal of Clinical Investigation|September 1, 1996
Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltiprazP J O'Dwyer, C E Szarka, K S Yao, et al.
Schizophrenia Research|July 23, 2016
Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processingAmanda McCleery, Junghee Lee, Alan P Fiske, et al.
Schizophrenia Research|February 26, 2019
The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trialDestiny L Peterson, Christopher A Webb, Jared W Keeley, et al.
Schizophrenia Bulletin|February 25, 2011
Social cognition in schizophrenia, Part 1: performance across phase of illnessMichael F Green, Carrie E Bearden, Tyrone D Cannon, et al.
Journal of Gastrointestinal Oncology|November 16, 2023
Identification of an optimal mutant allele frequency to detect activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomasBennett A Caughey, Kumiko Umemoto, Michelle F Green, et al.
Molecular Diagnosis & Therapy|June 7, 2025
Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue UsageMichelle F Green, Zachary D Wallen, Heidi C Ko, et al.
Biological Psychiatry|May 3, 2011
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disordersCameron S Carter, Deanna M Barch, Edward Bullmore, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 12, 2021
The clinical characterization of the patient with primary psychosis aimed at personalization of managementMario Maj, Jim van Os, Marc De Hert, et al.
Journal of Abnormal Psychology|October 15, 2014
Social cognition and functional outcome in schizophrenia: The moderating role of cardiac vagal toneHolly K Hamilton, Jane C Sun, Michael F Green, et al.
Biological Psychiatry|September 1, 2004
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteriaMichael F Green, Keith H Nuechterlein, James M Gold, et al.
Pageof 97